non-canonical HLA peptides in cancer
benchmark · DDA · 1 version · 4 papers
HLA class I and II peptides from tumour-affected and healthy tissue, the immunopeptidomics arm.
| Kind | benchmark |
| Acquisition | DDA |
| Organisms | Homo sapiens (human) |
HLA class I and II peptides from tumour-affected and healthy tissue, the immunopeptidomics arm.
Versions
as deposited
Where it lives:
- PRIDE · PXD013649
Used by (4)
- TIPs: a deep learning-guided proteogenomic framework to expand the landscape of transposable element-derived antigens with immunopeptidomics (2026) peer-reviewed as deposited
- A living proteomics benchmark for comprehensive evaluation of deep learning-based de novo peptide sequencing tools (2026) preprint as deposited
- MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer (2024) peer-reviewed as deposited
- MARS: Improved De Novo Peptide Candidate Selection for Non-Canonical Antigen Target Discovery in Cancer (2022) preprint as deposited
Methods on these papers (3)
- Living proteomics benchmark benchmark
- MARS downstream-application
- TIPs downstream-application
Taken from the describing links only, so a paper that merely ran a tool on this data does not make that tool a method of it.